Pre-made Ixekizumab biosimilar ( Whole mAb, anti-IL17A therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-286
Anti-IL17A therapeutic antibody (Pre-made Ixekizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody. The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL17A therapeutic antibody (Pre-made Ixekizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||6nov:AB|
|99% SI Structure||6nou:AA|
|95-98% SI Structure||None|
|Companies||Eli Lilly;Oregon Health & Science University;Torii Pharmaceutical|
|Conditions Approved||Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis|
|Conditions Active||Ankylosing spondylitis;Spondylarthritis;Bullous pemphigoid;Pityriasis rubra pilaris;Pyoderma gangrenosum;Rheumatoid arthritis|